## **Core Concept**
Thromboxane A2 (TXA2) is a type of eicosanoid that plays a significant role in platelet aggregation and blood clotting. It is produced by platelets and has potent effects on vascular tone and platelet function.

## **Why the Correct Answer is Right**
Thromboxane A2 is indeed **formed by platelets** (Option A) through the action of the enzyme thromboxane synthase on prostaglandin H2 (PGH2), which is derived from arachidonic acid via the cyclooxygenase (COX) pathway. Specifically, it is **formed from PGG2/PGH2** (Option B), making both A and B correct statements. TXA2 promotes platelet aggregation and is **prothrombogenic** (Option C), meaning it encourages the formation of blood clots. Additionally, TXA2 acts as a **vasoconstrictor** (Option D), causing blood vessels to constrict. Therefore, the correct answers encompass the formation, function, and effects of TXA2.

## **Why Each Wrong Option is Incorrect**
- **Option E:** Vasodilator - This is incorrect because thromboxane A2 is known for causing vasoconstriction, not vasodilation.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that thromboxane A2 has a short half-life (about 30 seconds) but exerts potent effects on platelet aggregation and vascular tone. Inhibitors of TXA2 synthesis or action, such as low-dose aspirin, are used to prevent thrombotic events.

## **Correct Answer:** D.